ALX Oncology (NASDAQ:ALXO - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.55) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.17, Zacks reports.
ALX Oncology Trading Down 11.9 %
NASDAQ ALXO traded down $0.13 on Monday, reaching $0.93. The company had a trading volume of 839,383 shares, compared to its average volume of 977,599. ALX Oncology has a 52 week low of $0.93 and a 52 week high of $17.83. The stock's 50 day moving average is $1.39 and its 200-day moving average is $1.60. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. The stock has a market cap of $49.26 million, a price-to-earnings ratio of -0.31 and a beta of 1.01.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on ALXO shares. Stifel Nicolaus reduced their target price on shares of ALX Oncology from $3.00 to $1.50 and set a "hold" rating on the stock in a research report on Friday. HC Wainwright reaffirmed a "buy" rating and set a $5.00 price objective on shares of ALX Oncology in a report on Friday. Jefferies Financial Group upgraded ALX Oncology from a "hold" rating to a "buy" rating and increased their price objective for the company from $2.00 to $3.00 in a research report on Thursday. Piper Sandler boosted their target price on ALX Oncology from $8.00 to $9.00 and gave the stock an "overweight" rating in a research report on Thursday. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of ALX Oncology in a report on Friday, January 24th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $4.14.
View Our Latest Stock Report on ALXO
ALX Oncology Company Profile
(
Get Free Report)
ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.
Featured Stories
Before you consider ALX Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ALX Oncology wasn't on the list.
While ALX Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
